Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Trial Details

NCT ID
NCT07149363
Phase
PHASE2
Sponsor
Alliance Foundation Trials, LLC.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Durvalumab 50 MG/ML
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Scarborough, Maine, United States|43.57814,-70.32172
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Body weight \>30 kg.
  • Must have a life expectancy of at least 12 weeks.
  • Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →